Business Context and Reporting Period
This Form 8-K, dated November 30, 2018, is filed by Altimmune, Inc. to provide summary consolidated financial data retroactively adjusted for a one-for-thirty reverse stock split effective September 13, 2018. The filing presents historical data for the nine months ended September 30, 2018 and 2017, and the full years ended December 31, 2017, 2016, and 2015.
Key Financial Metrics
| Period | Revenue | Net Loss | Net Loss to Common | EPS (Basic/Diluted) |
|---|---|---|---|---|
| 9 Months Ended Sep 30, 2018 | $7,742,514 | $(14,663,529) | $(17,190,804) | $(17.48) |
| 9 Months Ended Sep 30, 2017 | $7,929,484 | $(37,594,401) | $(39,719,542) | $(102.76) |
| Year Ended Dec 31, 2017 | $10,738,322 | $(46,425,390) | $(51,355,400) | $(118.91) |
| Year Ended Dec 31, 2016 | $3,236,175 | $(11,086,812) | $(11,455,360) | $(48.66) |
| Year Ended Dec 31, 2015 | $4,654,468 | $(6,648,902) | $(6,787,457) | $(34.45) |
Operating Expenses (9 Months 2018 vs 2017): Total operating expenses decreased from $47.4 million to $23.2 million, primarily driven by a reduction in goodwill impairment charges from $26.6 million to $0.5 million. Research and development expenses increased slightly to $15.4 million, while general and administrative expenses rose to $7.3 million.
Liquidity and Debt: The filing text does not provide specific values for cash flow, debt levels, or liquidity ratios.
Material Changes
- Reverse Stock Split: All share and per-share amounts have been retroactively adjusted to reflect a one-for-thirty reverse stock split.
- Goodwill Impairment: The significant decrease in net loss for the nine months ended September 30, 2018, compared to the prior year, is largely attributable to the absence of the $26.6 million goodwill impairment charge recorded in the same period in 2017.
- Revenue Trend: Revenue for the nine months ended September 30, 2018, declined slightly by approximately 2.4% compared to the same period in 2017.
Outlook, Risks, and Unusual Items
Management Commentary: The Company states that historical results are not necessarily indicative of future results. The financial data presented is derived from audited 10-K and unaudited 10-Q filings and should be read in conjunction with those reports.
Unusual Items: The primary unusual item affecting comparability is the goodwill impairment charge of $26.6 million in the prior year period, which was not present in the current period.
Risks: The filing does not explicitly detail new risks beyond the standard disclaimer regarding the predictability of future results based on historical data.
Investor Verification Checklist
- Verify the impact of the one-for-thirty reverse stock split on current share ownership and trading price.
- Review the full Form 10-Q for the nine months ended September 30, 2018, to analyze cash flow and liquidity positions not detailed in this summary.
- Confirm the status of the Company's research and development pipeline, as R&D expenses remain a significant portion of operating costs.
- Examine the details of the goodwill impairment charges from 2017 to understand the valuation of acquired assets.